{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038312","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.816831+00:00","generated_at":"2026-06-12T06:04:11.197823+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulgent Genetics Q2 core revenue rises 48% to $67M; raises FY2023 guidance to $260M","bullets":["Total revenue $68M; core revenue $67M, up 48% YoY.","GAAP net loss $11.2M ($0.38/share); Non-GAAP loss $2.4M ($0.08/share).","Adjusted EBITDA loss $2.7M; cash flow from operations $9.7M.","Raises full-year 2023 core revenue guidance to $260M, narrows expected loss.","Cash, cash equivalents, and investments $846.8M as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038312","json":"https://secwatch.observer/filing/0000950170-23-038312.json","markdown":"https://secwatch.observer/filing/0000950170-23-038312.md","text":"https://secwatch.observer/filing/0000950170-23-038312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/0000950170-23-038312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/flgt-20230804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:04:11.197823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb2aee5c1af1dfaf266de5494c7824ff706cf66f","claim":"Fulgent Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue $68 million, net income GAAP loss of $11.2 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.","evidence_excerpt":"X-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, CA, August 4, 2023 — Fulgent Genetics, Inc.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/0000950170-23-038312-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$68 million"},{"label":"Net income","value":"GAAP loss of $11.2 million, or $0.38 per share"},{"label":"EPS","value":"$0.38 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}